Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2006 1
2007 1
2009 1
2010 2
2013 3
2014 2
2015 2
2016 1
2017 1
2019 1
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.
Lindén O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. Lindén O, et al. Among authors: bladt f. Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21. Cancer Biother Radiopharm. 2021. PMID: 33887152 Clinical Trial.
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. Falchook GS, et al. Among authors: bladt f. Clin Cancer Res. 2020 Mar 15;26(6):1237-1246. doi: 10.1158/1078-0432.CCR-19-2860. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822497 Clinical Trial.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. Yap TA, et al. Among authors: bladt f. Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28. Cancer Discov. 2021. PMID: 32988960 Free PMC article.
Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire.
Roy E, Togbe D, Holdorf AD, Trubetskoy D, Nabti S, Küblbeck G, Klevenz A, Kopp-Schneider A, Leithäuser F, Möller P, Bladt F, Hämmerling G, Arnold B, Pawson T, Tafuri A. Roy E, et al. Among authors: bladt f. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15529-34. doi: 10.1073/pnas.1009743107. Epub 2010 Aug 13. Proc Natl Acad Sci U S A. 2010. PMID: 20709959 Free PMC article.
Fine tuning of the threshold of T cell selection by the Nck adapters.
Roy E, Togbe D, Holdorf A, Trubetskoy D, Nabti S, Küblbeck G, Schmitt S, Kopp-Schneider A, Leithäuser F, Möller P, Bladt F, Hämmerling GJ, Arnold B, Pawson T, Tafuri A. Roy E, et al. Among authors: bladt f. J Immunol. 2010 Dec 15;185(12):7518-26. doi: 10.4049/jimmunol.1000008. Epub 2010 Nov 15. J Immunol. 2010. PMID: 21078909
c-Abl phosphorylates Dok1 to promote filopodia during cell spreading.
Woodring PJ, Meisenhelder J, Johnson SA, Zhou GL, Field J, Shah K, Bladt F, Pawson T, Niki M, Pandolfi PP, Wang JY, Hunter T. Woodring PJ, et al. Among authors: bladt f. J Cell Biol. 2004 May 24;165(4):493-503. doi: 10.1083/jcb.200312171. Epub 2004 May 17. J Cell Biol. 2004. PMID: 15148308 Free PMC article.
21 results